Palatin Technologies (PTN) Research & Development (2010 - 2026)
Palatin Technologies' (PTN) quarterly Research & Development came in at $3.5 million in Q1 2026, down 6.34% on a YoY basis from $3.8 million in Q1 2025, and down 18.58% quarter-over-quarter from $4.3 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Research & Development (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Research & Development for 16 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 6.34% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $12.3 million (down 29.93% YoY), and the FY2025 full-year result was $14.9 million, down 33.49% from the prior year.
- Research & Development fell to $3.5 million in Q1 2026 per PTN's latest filing, from $4.3 million in the prior quarter.
- Across five years, Research & Development topped out at $7.4 million in Q2 2022 and bottomed at $2.0 million in Q2 2025.
- Historically, Research & Development has averaged $4.9 million across 5 years, with a median of $4.8 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 113.57% in 2022, then slumped 57.83% in 2025.
- Over 5 years, Research & Development stood at $4.4 million in 2022, then increased by 27.17% to $5.6 million in 2023, then plunged by 38.25% to $3.4 million in 2024, then advanced by 25.96% to $4.3 million in 2025, then dropped by 18.58% to $3.5 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $3.5 million, $4.3 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 3.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 3.52 Mn |
| Dec 31, 2025 | 4.32 Mn |
| Sep 30, 2025 | 2.53 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 3.76 Mn |
| Dec 31, 2024 | 3.43 Mn |
| Sep 30, 2024 | 5.74 Mn |
| Jun 30, 2024 | 4.67 Mn |
| Mar 31, 2024 | 7.16 Mn |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 5.01 Mn |
| Jun 30, 2023 | 7.41 Mn |
| Mar 31, 2023 | 4.83 Mn |
| Dec 31, 2022 | 4.37 Mn |
| Sep 30, 2022 | 6.03 Mn |
| Jun 30, 2022 | 7.44 Mn |
| Mar 31, 2022 | 4.98 Mn |
| Dec 31, 2021 | 5.43 Mn |
| Sep 30, 2021 | 3.48 Mn |
| Jun 30, 2021 | 3.48 Mn |